These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37101291)

  • 21. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpelisib to treat breast cancer.
    Copur MS
    Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
    Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
    [No Abstract]   [Full Text] [Related]  

  • 24. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
    Pavlenko IA; Povilaitite PE; Makarevich NS; Kaciyaev VY; Petrov AV
    Arkh Patol; 2023; 85(4):5-11. PubMed ID: 37530184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
    Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpelisib for the treatment of
    Leenhardt F; Alexandre M; Jacot W
    Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
    Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
    Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
    Fillbrunn M; Signorovitch J; André F; Wang I; Lorenzo I; Ridolfi A; Park J; Dua A; Rugo HS
    BMC Cancer; 2022 Sep; 22(1):1002. PubMed ID: 36131248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
    Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
    Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
    Schwartzberg LS; Vidal GA
    Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.
    Dumont AG; Dumont SN; Trent JC
    Chin J Cancer; 2012 Jul; 31(7):327-34. PubMed ID: 22640628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.